FREQUENCY THERAPEUTICS INC (FREQ) Stock Analyst Ratings

NASDAQ:FREQ • US35803L1089

0.2996 USD
+0.02 (+5.94%)
Last: Nov 3, 2023, 08:00 PM
Buy % Consensus

43

ChartMill assigns a Buy % Consensus number of 43% to FREQ. The Buy consensus is the weighted average rating of the current analysts ratings.

  • Analysts have set a mean price target forecast of 0.51. This target is 70.23% above the current price.
  • FREQ was analyzed by 6 analysts. The buy percentage consensus is at 43. So analysts seem to be rather negative about FREQ.
  • In the previous month the buy percentage consensus was at a similar level.
  • FREQ was analyzed by 6 analysts. More opinions would make the average more meaningful.
FREQ Historical Analyst RatingsFREQ Historical Analyst Buy, Sell and Hold Ratings and number of analysts.Historical Monthly Analyst Rating -19 -17 -15 -13 -11 -9 -7 -5 -3 -1 2 4 6 8 10

Price Target & Forecast

Price Low Median Mean High 0.300.510.510.510.53 - 68.56% 70.23% 70.23% 75.23%
FREQ Current Analyst RatingFREQ Current Analyst Buy, Sell and Hold Ratings.Current Analyst Rating Strong Buy Buy Hold Sell Strong Sell 0.5 1 1.5 2 2.5
Up and Down Grades
Date Firm Action Rating
2023-09-26 Baird Downgrade Outperform -> Neutral
2023-02-15 Chardan Capital Downgrade Buy -> Neutral
2023-02-14 Oppenheimer Downgrade Outperform -> Perform
2023-02-14 Baird Maintains Outperform
2022-12-08 Chardan Capital Initiate Buy
2022-11-02 Baird Initiate Outperform
2022-05-24 Goldman Sachs Maintains Neutral
2021-09-22 Goldman Sachs Downgrade Buy -> Neutral
2021-03-24 Oppenheimer Maintains Outperform

FREQUENCY THERAPEUTICS INC / FREQ FAQ

What is the average price target for FREQUENCY THERAPEUTICS INC (FREQ) stock?

6 analysts have analysed FREQ and the average price target is 0.51 USD. This implies a price increase of 70.23% is expected in the next year compared to the current price of 0.2996.


What is the consensus rating for FREQ stock?

The consensus rating for FREQUENCY THERAPEUTICS INC (FREQ) is 43.3333 / 100 . This indicates that analysts generally have a neutral outlook on the stock.